Argenica Therapeutics (ASX:AGN) Accounts Payable: A$1.28 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:AGN Argenica Therapeutics Ltd ASX:AGN
27 GF Score
Price A$0.16
! 1 Warning Sign
View Full Analysis

What is Argenica Therapeutics Accounts Payable?

Argenica Therapeutics ASX:AGN +14.29% 27 Accounts Payable is A$1.28 Mil as of Dec. 2025. GuruFocus rates ASX:AGN with a GF Score™ of 27/100. The stock has 1 warning sign investors should review.

Argenica Therapeutics's Accounts Payable for the quarter that ended in Dec. 2025 was A$1.28 Mil.

Argenica Therapeutics's quarterly Accounts Payable increased from Dec. 2024 (A$1.43 Mil) to Jun. 2025 (A$2.88 Mil) but then declined from Jun. 2025 (A$2.88 Mil) to Dec. 2025 (A$1.28 Mil).

Argenica Therapeutics's annual Accounts Payable increased from Jun. 2023 (A$1.14 Mil) to Jun. 2024 (A$1.40 Mil) and increased from Jun. 2024 (A$1.40 Mil) to Jun. 2025 (A$2.88 Mil).

Argenica Therapeutics Accounts Payable Related Terms

Argenica Therapeutics Accounts Payable Historical Data

* Premium members only.

The historical data trend for Argenica Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Argenica Therapeutics Accounts Payable Chart

Argenica Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Accounts Payable
0.37 0.67 1.14 1.40 2.88

Argenica Therapeutics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 1.19 1.40 1.43 2.88 1.28
ASX:AGN
27GF Score
Argenica Therapeutics Ltd ASX:AGN
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Argenica Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of A$1.28 Mil mean?
Argenica Therapeutics (ASX:AGN) has a Accounts Payable of A$1.28 Mil as of Dec. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Argenica Therapeutics and its competitors.
Is Argenica Therapeutics' Accounts Payable too high?
Argenica Therapeutics' current Accounts Payable is A$1.28 Mil. Overall, Argenica Therapeutics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Argenica Therapeutics' Accounts Payable compare to VRTX and REGN?
Argenica Therapeutics' Accounts Payable of A$1.28 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Argenica Therapeutics and its competitors. Argenica Therapeutics's current Accounts Payable is A$1.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Argenica Therapeutics stock overvalued right now?
Argenica Therapeutics (ASX:AGN) has a current Accounts Payable of A$1.28 Mil. The current Accounts Payable is A$1.28 Mil. Argenica Therapeutics' overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Argenica Therapeutics (ASX:AGN), the current Accounts Payable is A$1.28 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Argenica Therapeutics Business Description

Address 117 Broadway, Unit 4, Nedlands, WA, AUS, 6009
Argenica Therapeutics Ltd is engaged in the research and development of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and its non-clinical studies to other indications and regulatory consultants.
27GF Score

Get the complete analysis for ASX:AGN

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.16
Price